[1]
|
Griveau, A., Seano, G., Shelton, S.J., Kupp, R., Jahangiri, A., Obernier, K., Krishnan, S., Lindberg, O.R., Yuen, T.J., Tien, A.-C., et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Mi-croenvironment. Cancer Cell, 33, 874-889. https://doi.org/10.1016/j.ccell.2018.03.020
|
[2]
|
Schiff, D. (2017) Low-Grade Gliomas. Continuum, 23, 1564-1579. https://doi.org/10.1212/CON.0000000000000537
|
[3]
|
Schiff, D., Van den Bent, M., Vogelbaum, M.A., Wick, W., Miller, C.R., Taphoorn, M., Pope, W., Brown, P.D., Platten, M., Jalali, R., et al. (2019) Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neu-ro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. Neuro-Oncology, 21, 837-853. https://doi.org/10.1093/neuonc/noz033
|
[4]
|
Jakola, A.S., Myrmel, K.S., Kloster, R., Torp, S.H., Lindal, S., Unsgard, G. and Solheim, O. (2012) Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas. JAMA, 308, 1881-1888. https://doi.org/10.1001/jama.2012.12807
|
[5]
|
Dhawan, S., Patil, C.G., Chen, C. and Venteicher, A.S. (2020) Early Versus Delayed Postoperative Radiotherapy for Treatment of Low-Grade Gliomas. Cochrane Database of Systematic Reviews, No. 1, Article No. CD009229.
https://doi.org/10.1002/14651858.CD009229.pub3
|
[6]
|
Nejo, T., Matsushita, H., Karasaki, T., Nomura, M., Saito, K., Tanaka, S., Takayanagi, S., Hana, T., Takahashi, S., Kitagawa, Y., et al. (2019) Reduced Neoantigen Expression Re-vealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. Cancer Immunology Research, 7, 1148-1161.
https://doi.org/10.1158/2326-6066.CIR-18-0599
|
[7]
|
Appolloni, I., Alessandrini, F., Ceresa, D., Marubbi, D., Gambini, E., Reverberi, D., Loiacono, F. and Malatesta, P. (2019) Progression from Low- to High-Grade in a Glioblas-toma Model Reveals the Pivotal Role of Immunoediting. Cancer Letters, 442, 213-221. https://doi.org/10.1016/j.canlet.2018.10.006
|
[8]
|
Timpl, R., Rohde, H., Robey, P.G., Rennard, S.I., Foidart, J.M. and Martin, G.R. (1979) Laminin—A Glycoprotein from Basement Membranes. The Journal of Biological Chemistry, 254, 9933-9937.
https://doi.org/10.1016/S0021-9258(19)83607-4
|
[9]
|
Chung, A.E., Jaffe, R., Freeman, I.L., Vergnes, J.P., Bra-ginski, J.E. and Carlin, B. (1979) Properties of a Basement Membrane-Related Glycoprotein Synthesized in Culture by a Mouse Embryonal Carcinoma-Derived Cell Line. Cell, 16, 277-287. https://doi.org/10.1016/0092-8674(79)90005-9
|
[10]
|
Aumailley, M., Bruckner-Tuderman, L., Carter, W.G., Deutz-mann, R., Edgar, D., Ekblom, P., Engel, J., Engvall, E., Hohenester, E., Jones, J.C., et al. (2005) A Simplified Laminin Nomenclature. Matrix Biology, 24, 326-332.
https://doi.org/10.1016/j.matbio.2005.05.006
|
[11]
|
Yurchenco, P.D. (2011) Basement Membranes: Cell Scaffold-ings and Signaling Platforms. Cold Spring Harbor Perspectives Biology, 3, a004911. https://doi.org/10.1101/cshperspect.a004911
|
[12]
|
Qin, Y., Rodin, S., Simonson, O.E. and Hollande, F. (2017) Laminins and Cancer Stem Cells: Partners in Crime? Seminars in Cancer Biology, 45, 3-12. https://doi.org/10.1016/j.semcancer.2016.07.004
|
[13]
|
Korbakis, D., Dimitromanolakis, A., Prassas, I., Davis, G.J., Barber, E., Reckamp, K.L., Blasutig, I. and Diamandis, E.P. (2015) Serum LAMC2 Enhances the Prognostic Value of a Multi-Parametric Panel in Non-Small Cell Lung Cancer. British Journal of Cancer, 113, 484-491. https://doi.org/10.1038/bjc.2015.171
|
[14]
|
Bello, L., Giussani, C., Carrabba, G., Pluderi, M., Costa, F. and Bikfalvi, A. (2004) Angiogenesis and Invasion in Gliomas. Cancer Treatment and Research, 117, 263-284. https://doi.org/10.1007/978-1-4419-8871-3_16
|
[15]
|
Onishi, M., Kurozumi, K., Ichikawa, T. and Date, I. (2013) Mechanisms of Tumor Development and Anti-Angiogenic Therapy in Glioblastoma Multiforme. Neurologia Medi-co-Chirurgica, 53, 755-763.
https://doi.org/10.2176/nmc.ra2013-0200
|
[16]
|
Kurozumi, K., Onishi, M., Ichikawa, T., Fujii, K., Ishida, J., Shima-zu, Y. and Date, I. (2013) [III. Molecular Targeting Therapy for Glioma-Bevacizumab and Cilengitide]. Japanese Journal of Cancer and Chemotherapy, 40, 718-722.
|
[17]
|
Varner, J.A. and Cheresh, D.A. (1996) Integrins and Cancer. Current Opinion in Cell Biology, 8, 724-730.
https://doi.org/10.1016/S0955-0674(96)80115-3
|
[18]
|
Lu, P., Weaver, V.M. and Werb, Z. (2012) The Extracellular Matrix: A Dynamic Niche in Cancer Progression. Journal of Cell Biology, 196, 395-406. https://doi.org/10.1083/jcb.201102147
|
[19]
|
Patarroyo, M., Tryggvason, K. and Virtanen, I. (2002) Laminin Isoforms in Tumor Invasion, Angiogenesis and Metastasis. Seminars in Cancer Biology, 12, 197-207. https://doi.org/10.1016/S1044-579X(02)00023-8
|
[20]
|
Oikawa, Y., Hansson, J., Sasaki, T., Rousselle, P., Do-mogatskaya, A., Rodin, S., Tryggvason, K. and Patarroyo, M. (2011) Melanoma Cells Produce Multiple Laminin Isoforms and Strongly Migrate on α5 Laminin(s) via Several Integrin Receptors. Experimental Cell Research, 317, 1119-1133. https://doi.org/10.1016/j.yexcr.2010.12.019
|
[21]
|
Givant-Horwitz, V., Davidson, B. and Reich, R. (2004) Laminin-Induced Signaling in Tumor Cells: The Role of the M(r) 67,000 Laminin Receptor. Cancer Research, 64, 3572-3579. https://doi.org/10.1158/0008-5472.CAN-03-3424
|
[22]
|
Takada, Y., Ye, X. and Simon, S. (2007) The Integrins. Genome Biology, 8, Article No. 215.
https://doi.org/10.1186/gb-2007-8-5-215
|
[23]
|
Hood, J.D. and Cheresh, D.A. (2002) Role of Integrins in Cell Inva-sion and Migration. Nature Reviews Cancer, 2, 91-100. https://doi.org/10.1038/nrc727
|
[24]
|
Schnell, O., Krebs, B., Wagner, E., Romagna, A., Beer, A.J., Grau, S.J., Thon, N., Goetz, C., Kretzschmar, H.A., Tonn, J.C. and Goldbrunner, R.H. (2008) Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is Not Restricted to Tumor Vas-culature. Brain Pathology, 18, 378-386. https://doi.org/10.1111/j.1750-3639.2008.00137.x
|
[25]
|
Kurozumi, K., Ichikawa, T., Onishi, M., Fujii, K. and Date, I. (2012) Cilengitide Treatment for Malignant Glioma: Current Status and Future Direction. Neurologia Medico-Chirurgica, 52, 539-547. https://doi.org/10.2176/nmc.52.539
|
[26]
|
Meyer, A., Auernheimer, J., Modlinger, A. and Kessler, H. (2006) Targeting RGD Recognizing Integrins: Drug Development, Bio-material Research, Tumor Imaging and Targeting. Current Pharmaceutical Design, 12, 2723-2747.
https://doi.org/10.2174/138161206777947740
|
[27]
|
Leavesley, D.I., Ferguson, G.D., Wayner, E.A. and Cheresh, D.A. (1992) Requirement of the Integrin β3 Subunit for Carcinoma Cell Spreading or Migration on Vitronectin and Fi-brinogen. Journal of Cell Biology, 117, 1101-1107.
https://doi.org/10.1083/jcb.117.5.1101
|
[28]
|
Tabatabai, G., Weller, M., Nabors, B., Picard, M., Reardon, D., Mik-kelsen, T., Ruegg, C. and Stupp, R. (2010) Targeting Integrins in Malignant Glioma. Targeted Oncology, 5, 175-181. https://doi.org/10.1007/s11523-010-0156-3
|
[29]
|
MacDonald, T.J., Taga, T., Shimada, H., Tabrizi, P., Zlokovic, B.V., Cheresh, D.A. and Laug, W.E. (2001) Preferential susceptibility of Brain Tumors to the Antiangiogenic Effects of an αv Integrin Antagonist. Neurosurgery, 48, 151-157.
https://doi.org/10.1227/00006123-200101000-00026
|
[30]
|
Onishi, M., Kurozumi, K., Ichikawa, T., Michiue, H., Fujii, K., Ishida, J., Shimazu, Y., Chiocca, E.A., Kaur, B. and Date, I. (2013) Gene Expression Profiling of the An-ti-Glioma Effect of Cilengitide. SpringerPlus, 2, Article No. 160.
https://doi.org/10.1186/2193-1801-2-160
|